Tenderwize
Zurück zur Suche

Non-exclusive discount agreement for Nadroparin

AOK Niedersachsen. Die Gesundheitskasse.·Hannover, Germany·Deadline Oct 27, 2026 · 63 days left·Open·Supplies·Framework
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Nadroparin (ATC-Code: B01AB06).

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

40 / 100

Komplexität

20 / 100

Risikofaktoren

Open-house contracts terminate automatically when exclusive discount contracts take effect, which may happen 6-8 months...

Since the agreement is non-exclusive and open to all, there is no minimum purchase commitment from the buyer.

No procurement documents available

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Dec 2026
  • Supply of Nadroparin (ATC B01AB06) under a non-exclusive discount agreement
  • Open-house model with uniform conditions for all participants
Vollständige Zusammenfassung anzeigen

This is a non-exclusive discount agreement (open-house model) for pharmaceutical products containing Nadroparin (ATC B01AB06) offered by AOK Niedersachsen. It is a bridge between patent expiry and exclusive contracts. Any pharmaceutical entrepreneur meeting eligibility can join at any time from 2025-01-01 to 2026-12-31. The first entry deadline is 2024-11-27. The contract is not a public procurement; it uses a transparency publication.

Risiken

Open-house contracts terminate automatically when exclusive discount contracts take effect, which may happen 6-8 months...

Since the agreement is non-exclusive and open to all, there is no minimum purchase commitment from the buyer.

No procurement documents available

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Must be a pharmaceutical entrepreneur as defined in § 4 Abs. 18 AMG
  • Must have seat in EU/EEA or Germany
  • Only the active ingredient Nadroparin (ATC B01AB06) is covered

Zuschlagskriterien

Lot 1

Price - no further details

Auftraggeber

Lose (1)

LOT-0000

Non-exclusive discount agreement for Nadroparin

Open-house model for Nadroparin (ATC B01AB06) from 2025-01-01 to 2026-12-31. All pharmaceutical companies may join under uniform conditions. Contracts end automatically when exclusive contracts come into effect. The first sign-up deadline is 2024-11-27; later entry possible monthly with 35-day advance notice.

SuppliesFrameworkEU fundedElectronic submission

Ort

DE929, Germany

Dauer

Dec 2024 - Dec 2026

Kategorie

Pharmaceutical products

Zuschlagskriterien

Price

Frist

Expired Nov 27, 2024

Vergabedetails

Veröffentlichungsdatum
04 Nov 2024
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
671589-2024

Ähnliche Ausschreibungen